Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
NEW YORK, March 07, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired common stock of ReWalk Robotics Ltd. (“ReWalk”) (NASDAQ:RWLK) pursuant and/or traceable to the Company’s Stock Offering on or about September 12, 2014.
You are hereby notified that a securities action Deng, et al. v. ReWalk Robotics, Ltd., et al. (Case No. 1:17-cv-10169) has commenced in the USDC for the District Massachusetts. If you purchased or otherwise acquired ReWalk common stock pursuant to the Offering, your rights may be affected by this action. To get more information go to: zlk.9nl.com/rewalk-robotics-rwlk.
The complaint alleges that the Registration Statement and Prospectus issued in connection with the Initial Public Offering failed to disclose material information, including that ReWalk was unprepared and/or unable to comply with “special controls” requirements or to provide the U.S. Food and Drug Administration with a postmarket surveillance study as required by the FDA for the Company to maintain ongoing sales of its products.
If you suffered a loss in ReWalk you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
